Morphotek and Fox Chase Cancer Centre (FCCC) have entered a sponsored research agreement (SRA) to advance research on immunosuppressive effects of tumour shed antigens to develop improvised cancer therapies.
According to the agreement, the partners will jointly work on expanding knowledge of the biological pathways to identify tumour molecular and cellular signatures and suppressed immune responses in patients to tumours during immune-based therapies.
Go deeper with GlobalData
The agreement enables the two partners to further study the efficacy of the therapies.
PRA Health Sciences and Takeda Pharmaceutical Company have entered an agreement to further advance the development of the latter’s product pipeline, clinical studies of marketed products and post-approval needs.
Pursuant to the agreement, PRA Health Sciences will support the pipeline studies for Takeda by using its internal resources and will also provide regulatory pharmacovigilance services for its marketed and development product line.
See Also:
Celon Pharma plans to raise gross proceeds of $63.3m through the initial public offering (IPO) of 15 million of its series B shares.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company plans to use the proceeds to fund its clinical studies programme.
Agios Pharmaceuticals has announced an underwritten public offering of its common stock shares. The company expects to raise up to $150m through the offering.
The pharmaceutical company plans to use the proceeds for general corporate purposes and to further advance its ongoing development and pre-commercial activities of AG-120 and AG-221, PK deficiency programme, and early candidate programme.
Avitide plans to expand its affinity resin discovery platform and manufacturing operations through the funds raised from a Series D venture financing round.
The financing round was led by Mithril Capital Management.
Image: PRA Health Sciences and Takeda Pharmaceutical Company have entered an agreement to further advance the development of the latter's product development. Photo: courtesy of Lombroso via Wikipedia.
